Cargando…
Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer
We report on a 90-year-old male patient with a ROS1-translocated adenocarcinoma of the lung who was treated with crizotinib as first-line therapy. After 11 months of treatment, we noticed complete metabolic response as measured by (18)F-FDG-PET/CT scan and a partial response according to RECIST crit...
Autores principales: | Overbeck, Tobias R., Schmitz, Katja, Engelke, Christoph, Sahlmann, Carsten-Oliver, Hugo, Sara, Kellner, Laura, Trümper, Lorenz, Schildhaus, Hans-Ulrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821145/ https://www.ncbi.nlm.nih.gov/pubmed/27065847 http://dx.doi.org/10.1159/000444745 |
Ejemplares similares
-
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016) -
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001
por: Carter, Corey A., et al.
Publicado: (2016) -
Treatment of Focal Segmental Glomerulosclerosis Recurrence in the Renal Allograft: A Report of Two Cases
por: Tran, Minh-Ha, et al.
Publicado: (2016) -
Pure Lymphoepithelioma-Like Carcinoma Originating from the Urinary Bladder
por: Nagai, Takashi, et al.
Publicado: (2016) -
Improved Vision from Severe Compressive Optic Neuropathy by Apical Cavernous Hemangioma
por: Kang, Hyera, et al.
Publicado: (2016)